European Respiratory Journal

Journal

Publication Venue For

  • Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. 2019
  • Effect of daily azithromycin therapy and adherence on readmission risk in COPD.  53. 2019
  • Pulmonary fibrosis: "idiopathic" is not "cryptogenic".  53. 2019
  • Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?.  53. 2019
  • Inflammation and endothelial activation in early adulthood are associated with future emphysema: the CARDIA Lung Study.  53. 2019
  • Post-approval upper airway stimulation predictors of treatment effectiveness in the ADHERE registry.  53. 2019
  • Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS.  52. 2018
  • Fibroblast growth factor 23 and Klotho contribute to airway inflammation.  52. 2018
  • A clean sweep: Mucin bundles clear the airway.  52. 2018
  • Cigarette smoking and response to inhaled corticosteroids in COPD.  51. 2018
  • ERS/ATS workshop report on respiratory health effects of household air pollution.  51. 2018
  • What's in a name? That which we call IPF, by any other name would act the same.  51. 2018
  • Chest computed tomography-derived low fat-free mass index and mortality in COPD.  50. 2017
  • Airway microbiota across age and disease spectrum in cystic fibrosis..  50. 2017
  • High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis.  50. 2017
  • In Rotterdam, size really does matter: implications of pulmonary artery enlargement on mortality.  49. 2017
  • Doxycycline improves clinical outcomes during cystic fibrosis exacerbations.  49. 2017
  • Beta-blockers in COPD: Time for reappraisal.  48:880-888. 2016
  • A phase III randomised controlled trial of single-dose triple therapy in COPD: The IMPACT protocol.  48:320-330. 2016
  • FG-3019 anti-connective tissue growth factor monoclonal antibody: Results of an open-label clinical trial in idiopathic pulmonary fibrosis.  47:1481-1491. 2016
  • Sex-specific features of emphysema among current and former smokers with COPD.  47:104-112. 2016
  • A randomised trial of lung sealant versus medical therapy for advanced emphysema.  46:651-662. 2015
  • Continuous fat-free mass decline in COPD: Fact or fiction?.  46:1496-1498. 2015
  • Outcomes of β-blocker use in pulmonary arterial hypertension: A propensity-matched analysis.  46:750-760. 2015
  • The clinical and genetic features of COPD-asthma overlap syndrome.  44:341-350. 2014
  • Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice.  43:1448-1458. 2014
  • Pulmonary matrix metalloproteinase-9 activity in mechanically ventilated children with respiratory syncytial virus.  43:1086-1096. 2014
  • Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.  44:1296-1307. 2014
  • Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial.  43:295-298. 2014
  • Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial.  42:1622-1632. 2013
  • CFTR biomarkers: Time for promotion to surrogate end-point?.  41:203-216. 2013
  • The risk of tuberculosis in transplant candidates and recipients: A TBNET consensus statement.  40:990-1013. 2012
  • CXCR1 and CXCR2 haplotypes synergistically modulate cystic fibrosis lung disease.  39:1385-1390. 2012
  • Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis.  39:133-140. 2012
  • Series "matrix metalloproteinases in lung health and disease": The role of matrix metalloproteinases in cystic fibrosis lung disease.  38:721-727. 2011
  • Lean mass predicts asthma better than fat mass among females.  37:65-71. 2011
  • Combined airway and oesophageal stenting in malignant airway-oesophageal fistulas: A prospective study.  36:1370-1374. 2010
  • Biologic lung volume reduction therapy for advanced homogeneous emphysema.  36:20-27. 2010
  • Inhibition of airway proteases in cystic fibrosis lung disease.  32:783-795. 2008
  • Erratum: "Talc mediates angiostasis in malignant pleural effusions via endostatin induction" (European Respiratory Journal (2007) vol. 29 (761-769)).  29:1286. 2007
  • Talc mediates angiostasis in malignant pleural effusions via endostatin induction.  29:761-769. 2007
  • Immunological mechanisms in pleural disease.  21:539-544. 2003
  • Management of malignant pleural effusions.  18:402-419. 2001
  • Haemoptysis associated with pulmonary varices: Demonstration using computed tomographic angiography.  12:989-992. 1998
  • Immunobiology of pleural inflammation: Potential implications for pathogenesis, diagnosis and therapy.  10:2411-2418. 1997
  • Pleurodesis: State of the art.  10:1648-1654. 1997
  • Alveolar cell population in HIV infected patients.  4:639-642. 1991
  • International Standard Serial Number (issn)

  • 0903-1936
  • Electronic International Standard Serial Number (eissn)

  • 1399-3003